Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

Alibaba's financial services spinoff is reportedly lining up an offering this year that would also represent an exit for China Life and China Post.

Lenovo, iFlytek, Alibaba and Tuling Century-backed AI processor provider Cambricon, valued at $2.5bn in 2018, floated on Shanghai's Star Market.

The co-working space provider, which counts a slew of corporates among its investors, will list on Nasdaq by merging with a SPAC in a deal jointly valuing them at $769m.

The robotics technology provider, a spinoff from automotive manufacturer Chery, plans to float in a Shanghai offering that will also allow Midea to exit.

Gilead-backed AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.

The Sompo, Relx and Fujitsu-backed big data analytics provider, valued at more than $20bn in 2015, has revealed it has confidentially filed for a public listing.

Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

Amgen-backed immuno-oncology spinout Immatics has gone public through a reverse merger with special purpose acquisition company Arya Sciences.